Impact of Leukemia and Lymphoma Society services on blood cancer patients
The Impact of a Non-Profit Cancer Advocacy Organization on Patient Reported Outcomes and Access to Care: A Multisite, Longitudinal Trial
This study is testing how the services provided by the Leukemia and Lymphoma Society can help people with blood cancers feel better and manage their care over six months.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Miami Academic / other |
| Drugs / interventions | CAR-T |
| Locations | 3 sites (Miami, Florida and 2 other locations) |
| Trial ID | NCT05745285 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate how the services and programs offered by the Leukemia and Lymphoma Society (LLS) affect patients with blood cancers, including leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. It focuses on aspects such as access to care, quality of life, and financial burdens faced by these patients. Participants will be followed for six months to assess the impact of LLS programs on their treatment experience and unmet needs.
Who should consider this trial
Good fit: Ideal candidates are patients currently receiving treatment for blood cancers who have unmet needs that LLS programs can address.
Not a fit: Patients who are not currently undergoing treatment for blood cancers or do not have unmet needs related to LLS services may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the support and resources available to blood cancer patients, improving their overall care and quality of life.
How similar studies have performed: While the specific impact of LLS services has not been extensively studied, similar programs have shown positive outcomes in supporting cancer patients in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Be diagnosed with, or have a recurrence of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN). * Have received, be receiving, or be planning to receive primary or relapse treatment for leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN) and meet at least one of the following criteria: * Be currently receiving treatment which started within the past 18 months OR * Be planning to start treatment within one month OR * Have received Bone Marrow Transplant or CAR-T cell therapy within the past 100 days. * Not be currently participating in any LLS programs or services * Be willing to be followed for 6 months * Speak English or Spanish Exclusion Criteria: * Are not diagnosed with, or have a recurrence of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN) * Do not meet at least one of the following criteria if treated or planning to get treated for leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN): * Be currently receiving treatment which started within the past 18 months OR * Be planning to start treatment within one month OR * Have received Bone Marrow Transplant or CAR-T cell therapy within the past 100 days. * Are currently participating in any LLS programs or services * Are not willing to be followed for 6 months * Do not speak English or Spanish.
Where this trial is running
Miami, Florida and 2 other locations
- Sylvester Comprehensive Cancer Center — Miami, Florida, United States (Recruiting)
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois, United States (Not_yet_recruiting)
- Mays Cancer Center at UT Health San Antonio — San Antonio, Texas, United States (Not_yet_recruiting)
Study contacts
- Principal investigator: Frank Penedo, PhD — University of Miami
- Study coordinator: Carlos Melara, MD
- Email: cam32407@med.miami.edu
- Phone: 3052438300
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.